Stock futures edged up in the premarket session on Monday, the first trading day of November, as investors started the month on a positive note and looked ahead to a busy week of earnings reports from major companies.
Here are some of Monday’s biggest stock movers:
Biggest stock gainers
- Berkshire Hathaway (BRK.A) (BRK.B) +2% – Shares rose after the company reported a 34% Y/Y jump in operating profit, driven largely by strong insurance underwriting results. The conglomerate’s cash holdings climbed to a record ~$382B as of September 30, 2025, up from ~$344B in Q2, with no share buybacks during the quarter. This marks the final quarterly report with Warren Buffett as CEO, as he prepares to step down at the end of the year, with Greg Abel set to assume the role and begin writing annual shareholder letters starting in 2026. Q3 operating earnings totaled $13.49B, rebounding after two quarters of declines, while net earnings attributable to shareholders rose 17% Y/Y to $30.8B.
-
NIO (NIO) +2% – Shares rose after the Chinese EV maker reported record monthly deliveries of 40,397 vehicles in October, up 92.6% Y/Y, bringing its total 2025 deliveries to 913,182. Across its three brands, NIO delivered 17,143 units, ONVO delivered 17,342, and FIREFLY delivered 5,912. The company highlighted strong demand for its ONVO L90 SUV, which has delivered over 10,000 units for three straight months since its launch in late July.
Biggest stock losers
-
Metsera (MTSR) -2% – Shares slipped after Pfizer (PFE) filed a lawsuit against Metsera and Novo Nordisk (NVO) in Delaware, alleging breach of contract, breach of fiduciary duty, and tortious interference after Metsera engaged with Novo on a competing takeover offer. Novo recently proposed a bid valuing Metsera at up to $77.75/share (~$9B), topping Pfizer’s offer of $47.50/share in cash (~$4.9B upfront) plus up to $22.50/share in contingent value rights. Pfizer argues Novo’s offer is not a superior proposal due to significant regulatory risks and maintains its agreement with Metsera remains binding. The lawsuit comes as Pfizer secured early HSR termination from the FTC, removing one regulatory hurdle for its planned acquisition.
More on related stocks:
- As Buffett Prepares To Step Down, Berkshire Hathaway Proves Its Strength
- Analysts Got It Wrong: Berkshire Hathaway Just Posted An Impressive Q3
- Metsera Becomes The Prize In Obesity’s Biggest Bidding War
- Pfizer sues Metsera, Novo Nordisk to block rival bid
- NIO sets new deliveries record in October with more than 40K vehicles